Drug Approval | August 28, 2023
Lupin receives approval from USFDA for Pirfenidone Tablets
This product will be manufactured at Lupin's Pithampur facility in India
This product will be manufactured at Lupin's Pithampur facility in India
Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Jeet will be a trusted partner in cardiovascular care
Lupin actively contributes to alleviating the burden of COPD for patients across the nation
The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.
Doxycycline Hyclate Delayed-Release Tablets USP (RLD Doryx ) had estimated annual sales of USD 9 million in the U.S. (IQVIA MAT June 2023).
Fluocinolone Acetonide Oil (RLD Derma-Smoothe/FS®) had estimated annual sales of USD 10 million in the U.S. (IQVIA MAT June 2023)
The company has reported total income of Rs. 4836.89 crores during the period ended June 30, 2023
Norgestrel and Ethinyl Estradiol Tablets USP (RLD Lo/Ovral-28) had an estimated annual sale of USD 34 million in the U.S. (IQVIA MAT Mar 2023)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
